199 related articles for article (PubMed ID: 32881430)
1. Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review.
Gamulin M; Nham E; Rkman D; Antunac Golubić Z; Likić R
Croat Med J; 2020 Aug; 61(4):326-332. PubMed ID: 32881430
[TBL] [Abstract][Full Text] [Related]
2. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data.
Hinata N; Yonese J; Masui S; Nakai Y; Shirotake S; Tatsugami K; Inamoto T; Nozawa M; Ueda K; Etsunaga T; Osawa T; Uemura M; Kimura G; Numakura K; Yamana K; Miyake H; Fukasawa S; Ochi K; Kaneko H; Uemura H
Int J Clin Oncol; 2020 Aug; 25(8):1533-1542. PubMed ID: 32519026
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
[TBL] [Abstract][Full Text] [Related]
4. Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Int J Clin Oncol; 2020 Apr; 25(4):705-712. PubMed ID: 31858306
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer.
Fujiwara R; Inamura K; Yuasa T; Numao N; Yamamoto S; Masuda H; Kawauchi A; Takeuchi K; Yonese J
Int J Clin Oncol; 2020 Jan; 25(1):151-157. PubMed ID: 31522314
[TBL] [Abstract][Full Text] [Related]
6. Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting.
Amores Bermúdez J; Osman García I; Unda Urzáiz M; Jiménez Marrero P; Ledo Cepero MJ; Llarena R; Flores Martín J; Abad Vivas-Pérez JI; Rodrigo Aliaga M; Juarez Soto A
Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):364-370. PubMed ID: 31097211
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
9. Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma.
José JM; Jose M; Silverio R; Federico V; Isabel C; Martin OA; Inmaculada B; Cristina C; Julia HC; Dolores TM; Jose G; Paola P; Nieves DP; Vicent A; Sara B; Sara M; Julián L; Manuel S; Del Carmen MM; Ángel CM; Vicente G
Clin Transl Oncol; 2020 Sep; 22(9):1517-1523. PubMed ID: 32048159
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes.
Numakura K; Kobayashi M; Hatakeyama S; Naito S; Horikawa Y; Tanaka T; Kamada S; Muto Y; Yamamoto R; Koizumi A; Nara T; Kanda S; Saito M; Narita S; Inoue T; Shimoda N; Tsuchiya N; Ohyama C; Habuchi T
Int J Clin Oncol; 2020 Aug; 25(8):1543-1550. PubMed ID: 32394047
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
[TBL] [Abstract][Full Text] [Related]
12. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.
Tachibana H; Kondo T; Ishihara H; Takagi T; Tanabe K
Clin Genitourin Cancer; 2019 Aug; 17(4):e772-e778. PubMed ID: 31101580
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
[TBL] [Abstract][Full Text] [Related]
15. Real-world safety and efficacy of nivolumab for ≥ 2nd line treatment of metastatic renal cell carcinoma: A retrospective cohort study in Croatia, Hungary, and Malta.
Vrdoljak E; Magri C; Gamulin M; Bošković L; Omrčen T; Bajić Ž; Dienes T; Geczi L
Neoplasma; 2021 Jan; 68(1):208-215. PubMed ID: 32940046
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function.
Sengul N; Gültürk I; Yilmaz M; Celik E; Paksoy N; Yekedüz E; Ürün Y; Basaran M; Özgüroğlu M
Actas Urol Esp (Engl Ed); 2024 May; 48(4):273-280. PubMed ID: 38570033
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
Noguchi G; Nakaigawa N; Umemoto S; Kobayashi K; Shibata Y; Tsutsumi S; Yasui M; Ohtake S; Suzuki T; Osaka K; Muraoka K; Hasumi H; Kondo K; Igarashi Y; Sasada T; Kishida T; Yao M
Cancer Chemother Pharmacol; 2020 Jul; 86(1):75-85. PubMed ID: 32537714
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
